Business Context and Reporting Period
Verastem, Inc. filed this Form 8-K on October 29, 2016, reporting the entry into a material definitive agreement. On this date, Verastem entered into an exclusive worldwide license agreement with Infinity Pharmaceuticals, Inc. (amended and restated on November 1, 2016) for the oncology drug duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma.
Key Financial Metrics and Obligations
This filing details contractual obligations rather than historical financial performance. Key financial terms include:
- Milestone Payments: $6 million upon completion of the DUO Study (Phase 3) if pre-specified criteria are met; $22 million upon regulatory approval of a new drug application.
- Payment Method: Payments may be made in cash or Company common stock. Stock issuances are subject to a 2.5% premium over the average closing price.
- Royalties: Mid-single digit to high-single digit royalties on worldwide net sales.
- Additional Royalties: 4% on worldwide net sales to reimburse Infinity for R&D costs owed to third parties (MICL and Purdue), reducing to 1% ("Trailing MICL Royalties") once reimbursed.
- Liability Cap: Infinity retains financial responsibility for shutting down certain specified clinical studies up to a maximum of $4.5 million.
Material Changes
Verastem has assumed financial and operational responsibility for the duvelisib program, including the ongoing DUO Study in relapsed/refractory chronic lymphocytic leukemia. Infinity is restricted from researching, developing, manufacturing, or commercializing duvelisib in any other indication.
Guidance, Risks, and Contingencies
- Termination Rights: Verastem may terminate the agreement with 180 days' notice after the DUO Study results are determined. Termination for convenience or breach may require transitioning the program back to Infinity at Verastem's cost.
- Royalty Reductions: Royalties are subject to 50% reductions if payable solely based on non-patent regulatory exclusivity or if third-party patent litigation damages/settlements are incurred (capped at 50% of payable amounts).
- Regulatory Filings: Any stock issued for milestone payments must be registered for resale with the SEC.
Investor Verification Checklist
- Verify the status and primary endpoint criteria of the DUO Study to assess the likelihood of the $6 million milestone payment.
- Confirm the current cash position and liquidity of Verastem to evaluate the ability to fund the $22 million approval milestone and ongoing royalties.
- Review the specific patent expiration dates and regulatory exclusivity periods for duvelisib to estimate the duration of royalty obligations.
- Monitor the reimbursement status of Infinity's obligations to MICL and Purdue to determine when the 4% additional royalty reduces to 1%.